Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1

Molecular Therapy

Volumn 3, Issue 4, 2001, Pages 531-535

  Maijgren Steffensson, Catharina ^a   Sönnerborg, Anders ^a   Vahlne, Anders ^a   Britton, Sven ^a   Larsson, Sten ^b   Ährlund Richter, Lars ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antiretroviral drugs; Gene therapy; HAART; HIV 1; Ribozyme

Indexed keywords

ANTIRETROVIRUS AGENT; GAG PROTEIN; NEF PROTEIN; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RIBOZYME; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; T LYMPHOCYTE; VIRUS INFECTION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034993681     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0286     Document Type: Article

References (32)

1. Adverse effects of antiretroviral therapy
2. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
3. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
4. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans
5. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
6. Latent reservoirs of HIV: Obstacles to eradication of virus
7. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
8. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
9. Antiretroviral drug resistance in HIV-1
10. Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors
11. Evolution of HIV-1 multidrug-resistant genotypes during combination therapy and after the cessation of antiretroviral drugs
12. Gene therapy for infectious diseases
13. Ribozyme therapeutics
14. Current developments and future prospects for HIV gene therapy using interfering RNA-based strategies
15. Ribozyme therapy for HIV infection
16. Progress toward gene therapy for HIV infection
17. The use of ribozymes in gene therapy approaches to AIDS
18. A novel ribozyme target site located in the HIV-1 nef open reading frame
19. Changing therapy in HIV
20. Antiretroviral drugs for AIDS
21. Current problems and the future of antiretroviral drug trials
22. Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas
23. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity
24. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
25. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
26. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
27. HIV protease inhibitor-related lipodystrophy syndrome
28. HIV-associated lipodystrophy syndrome
29. Retrovirally expressed anti-HIV ribozymes confer a selective survival advantage on CD4+ T cells in vitro
30. A controlled, phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA
31. Antiviral potency of drug-gene therapy combinations against human immunodeficiency virus type 1